The Côte d’Ivoire dual burden of disease (CoDuBu) study

ISRCTN ISRCTN87099939
DOI https://doi.org/10.1186/ISRCTN87099939
Secondary identifying numbers N/A
Submission date
26/07/2017
Registration date
27/07/2017
Last edited
30/10/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
The co-occurrence of infectious diseases and non-communicable diseases (not caused by infection) is poorly studied, despite the fact that this dual burden has become a reality for many low- and middle-income countries (LMICs). Even very little is known about how common infectious diseases (e.g. worms and malaria) and non-communicable diseases (e.g. high blood pressure and diabetes) influence each other. Repeated and chronic (long-term) infections that are common in LMICs may alter people’s susceptibility to diabetes and heart disease. Worm infections may shift the immune system into a direction protecting against inflammatory diseases, whereas repeated infections such as malaria may increase the risk of inflammatory diseases. Adults surviving often lethal infections in LMICs may have a genetically different susceptibility to age-related diseases (e.g. high blood pressue). As a result, people in LMICs may develop these diseases at different rates and at different ages than Western populations. If confirmed, this calls for changes in the provision of health services. The aim of this study is to carry out a survey of adults from rural and urban parts of the Taabo district in south-central Côte d’Ivoire to study the co-occurrence of worm infections and malaria with metabolic syndrome, high blood pressure and diabetes.

Who can participate?
Adults (aged at least 18) from three selected villages

What does the study involve?
The survey consists of health examinations to assess the incidence of high blood pressure, diabetes, worm and malaria infections, lifestyle and risks of infectious and non-communicable diseases. Confirmatory tests are provided as well as a free first month of treatment and enrolment into subsidized national care programmes. A biobank of collected biospecimens (e.g. stool and urine samples) is set up for future research.

What are the possible benefits and risks of participating?
All participants benefit from health examinations, laboratory tests, physician consultation and treatment, all free of charge. Participants receive health advice from the physician regardless of disease status. Participating health centres are equipped with diagnostic tools, and participating health workers are trained in non-communicable disease diagnosis and management. The biobank will improve local research. There are no specific risks associated with this study, although providing stool and urine samples might be perceived as shameful. Furthermore, common drugs used for the treatment of worms, malaria, diabetes and high blood pressure might result in some side effects, but these are usually few, short-lived and the benefits outweigh the risk of not being treated.

Where is the study run from?
The study is conducted in three rural communities located in the Taabo district in south-central Côte d'Ivoire

When is the study starting and how long is it expected to run for?
April 2017 to December 2017

Who is funding the study?
Novartis Foundation (Switzerland)

Who is the main contact?
Prof. Nicole Probst-Hensch

Contact information

Prof Nicole Probst-Hensch
Scientific

Socinstrasse 57
Basel
4051
Switzerland

Study information

Study designObservational cross-sectional survey
Primary study designObservational
Secondary study designCross sectional study
Study setting(s)Community
Study typePrevention
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleCo-occurrence of common chronic infections (soil-transmitted helminths and Plasmodium) and common non-communicable diseases (diabetes and hypertension) in rural and urban Côte d’Ivoire
Study acronymCoDuBu
Study objectivesRepeated and chronic infections that are common in low- and middle-income countries (LMICs) may alter the susceptibility to diabetes and cardiovascular diseases as well as their related phenotypes, albeit in an infection-specific manner. Adults surviving often lethal infections in the context of LMICs may have a genetically different susceptibility to diabetes and hypertension.
Ethics approval(s)1. Ethikkommission beider Basel (EKBB, Switzerland), 25/07/2011, ref: 2016-00143
2. Comité National d’Ethique et de la Recherche (CNER, Côte d’Ivoire), 24/03/2017, ref: 032/IMSHP/CNER-kp
Health condition(s) or problem(s) studiedNon-communicable diseases, infectious diseases
InterventionThe study involves a baseline cross-sectional survey which will be carried out in three selected villages in the Taabo HDSS, followed by the establishment of a biobank. The cross-sectional survey consists of health examination to determine anthropometric indices, metabolic syndrome, as well as helminthic and malaria infections. It will also include questionnaire survey with regard to lifestyle and risks of IDs and NCDs. Identified cases of ID and NCD will be managed accordingly. Confirmatory tests will be provided for NCD cases as well as free first month of treatment and enrolment into subsidized national care programmes. A biobank consisting of collected biospecimens will be set-up for future research into mechanisms incolved in ID-NCD interactions.
Intervention type
Primary outcome measureAll outcomes measured at baseline:
1. Hypertension, assessed using blood pressure monitor and questionnaire
2. Diabetes, assessed using blood glucose and glycosylated hemoglobin tests and questionnaire
3. Helminth infection, assessed using Kato-Katz stool test, Baermann stool test, medical test
4. Malaria, assessed using rapid diagnostic blood test and microscopy
Secondary outcome measuresNo secondary outcome measures
Overall study start date23/04/2017
Completion date31/12/2017

Eligibility

Participant type(s)All
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants1000
Key inclusion criteria1. Age >= 18 years
2. Residence in the selected communities
3. Written informed consent to participate
Key exclusion criteria1. Residence in the selected communities
2. No written informed consent to participate
Date of first enrolment23/04/2017
Date of final enrolment31/05/2017

Locations

Countries of recruitment

  • Côte d'Ivoire
  • Switzerland

Study participating centres

Swiss Tropical and Public Health Institute
Socinstrasse 57
Basel
4051
Switzerland
Centre Suisse de Recherches Scientifiques en Côte d'Ivoire
01
Abidjan
01 BP 1303
Côte d'Ivoire
Université Félix Houphouët-Boigny
22
Abidjan
BP1106
Institut National de Sante Publique
Abidjan
BP V 47
Côte d'Ivoire
Ligue Ivoirienne contre l’Hypertension artérielle et les Maladies Cardiovasculaires
01
Abidjan
BP 2858
Côte d'Ivoire
Institut Pasteur de Côte d'Ivoire
01
Abidjan
BP 490
Côte d'Ivoire

Sponsor information

Swiss Tropical and Public Health Institute
Research organisation

Socinstrasse 57
Basel
4051
Switzerland

Website http://www.swisstph.ch
ROR logo "ROR" https://ror.org/03adhka07

Funders

Funder type

Other

Novartis Foundation
Private sector organisation / International organizations
Location
Switzerland

Results and Publications

Intention to publish date31/12/2019
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryData sharing statement to be made available at a later date
Publication and dissemination planPlanned publication of study protocol and the study results in the peer-reviewed (whenever possible open-access) literature before the end of 2019.
IPD sharing planThe data sharing plans for the current study are unknown and will be made available at a later date.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 27/10/2017 Yes No

Editorial Notes

30/10/2017: Publication reference added.